187 related articles for article (PubMed ID: 9371334)
1. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.
Tanaka M; Onodera Y; Uchida Y; Sato K; Hayakawa I
Antimicrob Agents Chemother; 1997 Nov; 41(11):2362-6. PubMed ID: 9371334
[TBL] [Abstract][Full Text] [Related]
2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of quinolone resistance in Staphylococcus aureus.
Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
[TBL] [Abstract][Full Text] [Related]
4. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
[TBL] [Abstract][Full Text] [Related]
5. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
6. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
8. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
9. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.
Tanaka M; Sato K; Kimura Y; Hayakawa I; Osada Y; Nishino T
Antimicrob Agents Chemother; 1991 Jul; 35(7):1489-91. PubMed ID: 1656864
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
Akasaka T; Kurosaka S; Uchida Y; Tanaka M; Sato K; Hayakawa I
Antimicrob Agents Chemother; 1998 May; 42(5):1284-7. PubMed ID: 9593169
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
[TBL] [Abstract][Full Text] [Related]
13. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
Fukuda H; Hori S; Hiramatsu K
Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.
Onodera Y; Tanaka M; Sato K
J Antimicrob Chemother; 2001 Apr; 47(4):447-50. PubMed ID: 11266418
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
Yamagishi J; Kojima T; Oyamada Y; Fujimoto K; Hattori H; Nakamura S; Inoue M
Antimicrob Agents Chemother; 1996 May; 40(5):1157-63. PubMed ID: 8723458
[TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
[TBL] [Abstract][Full Text] [Related]
19. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Pan XS; Hamlyn PJ; Talens-Visconti R; Alovero FL; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.
Onodera Y; Okuda J; Tanaka M; Sato K
Antimicrob Agents Chemother; 2002 Jun; 46(6):1800-4. PubMed ID: 12019093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]